Friday March 20, 2020 0 comments
BOULDER/HERCULES, Calif. -- Biodesix in Boulder and California-based Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, today announced that in two studies published this month, ahead of peer-review, researchers in China reported that Bio-Rad’s QX200 Droplet Digital PCR (ddPCR) System showed superior sensitivity and precision for clinical detection of SARS-CoV-2 (the virus that causes COVID-19) compared to existing test methods that are performed using qPCR.
In the first study, clinicians in Wuhan, China observed that a subset of infected individuals who tested negative for COVID-19 using qPCR tested positive using ddPCR.
The findings suggest that ddPCR can reduce false negative results of COVID-19 without any increase to false positive results and could be a powerful complement to the current standard of testing.
The second study, led by the National Institute of Metrology and provincial CDCs in China, also concluded that Droplet Digital PCR significantly improves diagnostic detection accuracy of SARS-CoV-2 from 28.2% to 87.4%, thereby reducing false negatives.
They also found that Droplet Digital PCR is more sensitive and suitable for low virus load specimens from patients under isolation and observation even without any clinical symptoms.
“Bio-Rad is working to make ddPCR-based tests available for COVID-19 detection and is partnering with Biodesix in Colorado to bring an Emergency Use Authorization (EUA) test online,” said Norman Schwartz, Bio-Rad president and CEO.
“By more quickly identifying those who test positive for the virus, individuals can be quarantined and receive treatment as quickly as possible, helping to contain the spread of COVID-19.”